Thermo Fisher Scientific Announces Collaboration to Revolutionize Profiling of Large Plasma Sample Cohorts in Protein-based Clinical Research Studies
Q Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ Mass Spectrometer
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Thermo Fisher Scientific, the world leader in serving science, and Evosep, a leading provider of sample preparation technologies for protein-based clinical research, have entered into a collaboration to develop high-throughput clinical research proteomics workflows for profiling large plasma sample cohorts for proteomics, translational research and pharmaceutical applications.
Leveraging the advanced omics technologies offered by Thermo Fisher’s Precision Medicine Science Center and the clinical proteomics expertise of Evosep, the collaboration will set new standards for plasma analysis. Combining the Thermo Scientific Q Exactive HF-X mass spectrometer and the Evosep One liquid chromatography solution will enable the development of powerful, standardized and high-throughput analytical protocols for the rapid and efficient processing of the most challenging plasma samples.
“The increasing use of plasma samples in clinical proteomics applications requires high-throughput workflows for the analysis of large sample cohorts,” said Ken Miller, vice president, life sciences mass spectrometry marketing, Thermo Fisher Scientific. “Our work with Evosep aims to accelerate clinical proteomics through the development of standardized workflows our customers can rely on to drive improvements in disease research.”
Christian Ravnsborg, general manager and head of marketing at Evosep, said, “The collaboration with Thermo Fisher is in full alignment with Evosep’s vision to improve quality of life and patient care by radically innovating how protein-based clinical research is performed. Working closely with experts from Thermo Fisher’s Precision Medicine Science Center will allow us to develop new workflows to meet the growing analytical needs of our customers.”
Leveraging the advanced omics technologies offered by Thermo Fisher’s Precision Medicine Science Center and the clinical proteomics expertise of Evosep, the collaboration will set new standards for plasma analysis. Combining the Thermo Scientific Q Exactive HF-X mass spectrometer and the Evosep One liquid chromatography solution will enable the development of powerful, standardized and high-throughput analytical protocols for the rapid and efficient processing of the most challenging plasma samples.
“The increasing use of plasma samples in clinical proteomics applications requires high-throughput workflows for the analysis of large sample cohorts,” said Ken Miller, vice president, life sciences mass spectrometry marketing, Thermo Fisher Scientific. “Our work with Evosep aims to accelerate clinical proteomics through the development of standardized workflows our customers can rely on to drive improvements in disease research.”
Christian Ravnsborg, general manager and head of marketing at Evosep, said, “The collaboration with Thermo Fisher is in full alignment with Evosep’s vision to improve quality of life and patient care by radically innovating how protein-based clinical research is performed. Working closely with experts from Thermo Fisher’s Precision Medicine Science Center will allow us to develop new workflows to meet the growing analytical needs of our customers.”
